Cessna Caravan Flight Deck to Feature Cockpit Advancements, Enhancing Flight Experience for Pilots
22.7.2024 16:00:00 EEST | Business Wire | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced significant enhancements to its legendary Cessna Caravan and Cessna Grand Caravan EX utility turboprop aircraft. A brighter, modernized flight deck with new backlit panels, along with other amenities designed to elevate the pilot experience, are the direct result of continuous conversations with customers. The enhancements, which are expected to be available in 2025, will be standard on all new Caravan and Grand Caravan EX aircraft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722286058/en/
Textron Aviation | Cessna Grand Caravan EX & Cessna Caravan (Photo: Business Wire)
“The enhancements to the Cessna Caravan flight deck demonstrate our continued commitment to providing the best possible flight experience for our customers,” said Christopher Crow, vice president, Piston and Utility Sales. “Our ongoing investments in this family of aircraft continues to build on the Caravan’s nearly 40-year history of success as the utility aircraft of choice for customers around the world.”
One of the most notable changes to both aircraft is the all-new black cockpit panels, creating a more contemporary appearance. The Caravan will also have Electroluminescent Lighting panels to match current Grand Caravan EX models, providing additional backlight for greater visibility in dimly lit environments.
Other enhancements to the Cessna Caravan and Grand Caravan EX include:
- A wider cockpit boarding ladder for easier access to the captain’s side of the aircraft
- Four circular, adjustable air nozzles to replace the previous two rectangular cockpit air vents
- Two USB-C charging ports to replace the 12V power adapter on the lower center pedestal of the cockpit
- Two USB-C charging ports on the right-hand subpanel for the copilot
- Standard power headset jacks (LEMO plugs) alongside the existing General Aviation plugs, offering operators greater flexibility in powering active noise cancelling headsets
- Headset hooks underneath the cockpit glareshield
About the Cessna Caravan family of aircraft
The Cessna Caravan and Grand Caravan EX are versatile, highly practical aircraft used for a wide range of global missions. The Caravan family of aircraft has provided dependable service around the world for nearly four decades.
The Cessna Caravan platform has seen more than 3,000 aircraft delivered that are certified in 100 countries with nearly 24 million flight hours amassed worldwide since the aircraft was introduced. Caravans fulfill roles for a multitude of missions, ranging from flight training to recreation, commuter airlines to VIP transport, cargo carriers and humanitarian missions. The Grand Caravan EX aircraft is known for its dependable and efficient performance by regional airlines, charter operators, cargo carriers and special missions operators worldwide. The aircraft offers an impressive output of 867 horsepower and a rate of climb of 1,275 feet per minute.
About Textron Aviation
We inspire the journey of flight. For more than 95 years, Textron Aviation Inc., a Textron Inc. company, has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops, and high-performance pistons, to special mission, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable and flexible flight. For more information, visit www.txtav.com | www.defense.txtav.com | www.scorpionjet.com.
About Textron Inc.
Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, Arctic Cat, Textron Systems, and TRU Simulation. For more information, visit: www.textron.com.
Certain statements in this press release may project revenues or describe strategies, goals, outlook or other non-historical matters; these forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update them. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722286058/en/
Contacts
Media Contact:
Duane Frazier
+1.316.517.1114
dfrazier2@txtav.com
txtav.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Ftxtav.com&eshee
t=54097076&newsitemid=20240722286058&lan=en-US&anchor=txtav.com&index=9&md5=6fb3
68ecf20a5ef3de42d5657c6835a8
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom